We’re excited to collaborate with Daniel Rotroff, CTO at Clarified Precision Medicine, through the Arionkoder Reshape Health Grants.
Their mission is to make precision oncology accessible to all—matching cancer patients with the right treatments, powered by AI and Deep Learning.
We’re supporting two key initiatives:
🔹 Building a smart dashboard that analyzes patient treatment data.
🔹 Using AI to process large-scale datasets from healthcare systems and pharma partners, revealing how therapies perform and where improvements are needed.
We’re proud to stand behind this important work in advancing cancer care. Stay tuned for updates!
See the video transcript below:
My name is Daniel Rotroff, and I’m the Chief Technology Officer for Clarified Precision Medicine.
Clarified Precision Medicine aims to make sure that all cancer patients receive the right therapy for them at the right time during their course of treatment. So right now, when a patient is diagnosed with cancer, oftentimes they will have their tumor sequenced to identify mutations within the tumor that may make the tumor vulnerable to certain chemotherapies or targeted therapies. And so what happens, the results that come back are oftentimes very difficult and complex to interpret and they require a lot of expertise.
So we use our AI and our own curated knowledge base to identify based on this patient’s molecular tumor profile, you know, what are all the different therapeutic matches that they could have. And then based on the current knowledge that’s out there and our own history that we’ve captured in our database which therapies are most likely to be recommended highly.
Gaining those insights on how we can help influence practice to make sure these patients are getting on the right treatment is something we really wanna work with Arionkoder on developing those tools, so we can not only just create these reports more efficiently for patients, but really leverage the data that we’re generating to highlight where the gaps are and how we can help close them.
I hope we’ll work together to, you know, build on this platform that we’ve created to really help, you know, drive insights into clinical practice and close gaps in precision oncology.